Culley C. Carson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Culley C. Carson has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Ajay Nehra
Mayo Clinic
1 shared publication- Ajay Nehra
Rush University Medical Center
1 shared publication Arthur L Burnett
Johns Hopkins University
1 shared publicationC H Noh
1 shared publicationEric Wallen
Division of Urology|University of North Carolina
1 shared publicationJ. Slade Hubbard
Division of Urology|University of North Carolina
1 shared publication
Latest Publications
- 11 February 2013
- Published by Springer Nature
- p. 135-139
Male Factor Infertility
- 11 February 2013
- Published by Springer Nature
- p. 129-134
Erectile Dysfunction
- Open Access
- 5 December 2012
- Published by Springer Nature
The efficacy, safety and tolerability of PSD502 in subjects with premature ejaculation (PE)
- 5 December 2012
- Published by Springer Nature
Open AccessThe efficacy, safety and tolerability of PSD502 in subjects with premature ejaculation (PE)
- 1 December 2012
- Published by Elsevier in European Urology
- Vol. 62 (6) , 1199-1200
Re: Complex Artificial Urinary Sphincter Revision and Reimplantation Cases—How Do They Fare Compared to Virgin Cases?
- 1 December 2012
- Published by Elsevier in European Urology
- Vol. 62 (6) , 1199-1200
Re: Complex Artificial Urinary Sphincter Revision and Reimplantation Cases—How Do They Fare Compared to Virgin Cases?
- 1 March 2011
- Published by MRE Press in Journal of Men's Health
- Vol. 8 (1) , 2
Editor's Comments
- Open Access
- 1 July 2009
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 5 (3) , 535-545
Finasteride in the treatment of patients with benign prostatic hyperplasia: a review
Peer reviewed article authored by (Angela B Smith, Culley C Carson). Read article or submit your manuscript for publishing.
- 1 July 2009
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 5 (3) , 535-545
Open AccessFinasteride in the treatment of patients with benign prostatic hyperplasia: a review
Peer reviewed article authored by (Angela B Smith, Culley C Carson). Read article or submit your manuscript for publishing.
- 1 November 2007
- Published by Elsevier in Urologic Clinics of North America
- Vol. 34 (4) , 507-515
Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class
- 1 November 2007
- Published by Elsevier in Urologic Clinics of North America
- Vol. 34 (4) , 507-515
Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class
- 1 March 2006
- Published by North Carolina Institute of Medicine in North Carolina Medical Journal
- Vol. 67 (2) , 122-127
Carcinoma of the Prostate: Overview of the Most Common Malignancy in Men
- 1 March 2006
- Published by North Carolina Institute of Medicine in North Carolina Medical Journal
- Vol. 67 (2) , 122-127
Carcinoma of the Prostate: Overview of the Most Common Malignancy in Men
- 23 February 2006
- Published by Wiley in BJU International
- Vol. 97 (s2) , 39-43
Combination of phosphodiesterase‐5 inhibitors and α‐blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
As the prevalence of both erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) increases with age, physicians could be in the position to manage these two conditions simultaneously. Moreover, medical therapies for either one of these conditions can affect the other and this should be carefully considered when making treatment decisions. Pharmacotherapy for benign prostatic hyperplasia (BPH)/LUTS can cause side‐ effects affecting sexual function. Hence, 5α‐reductase inhibitors such as finasteride and dutasteride are associated with a greater risk of ED, ejaculatory disorders (EjD) and decreased libido than is placebo. Among α 1 ‐adrenergic blockers, tamsulosin is associated with an increased risk of EjD. However, some α 1 ‐adrenergic blockers can also have a positive impact on erection. This is the case for alfuzosin, which has been shown to enhance erectile function in experimental models, probably by reducing the sympathetic tone and thus relaxing corpus cavernosum smooth muscle cells. Phosphodiesterase 5 (PDE‐5) inhibitors are commonly used to treat ED. There is increasing evidence that they might also have a beneficial effect on LUTS, probably through the nitric‐oxide pathway. Nitric oxide is an important mediator of the relaxation of isolated bladder and urethral smooth muscle, and could modulate prostatic smooth muscle tone. α 1 ‐adrenergic blockers and PDE‐5 inhibitors can therefore have a positive impact on both ED and LUTS. Although placebo‐controlled studies are needed to confirm the impact of these drugs, alone or combined, on both ED and LUTS, this reinforces the need for a common approach to managing these two highly prevalent and bothersome conditions.
- 23 February 2006
- Published by Wiley in BJU International
- Vol. 97 (s2) , 39-43
Combination of phosphodiesterase‐5 inhibitors and α‐blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
As the prevalence of both erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) increases with age, physicians could be in the position to manage these two conditions simultaneously. Moreover, medical therapies for either one of these conditions can affect the other and this should be carefully considered when making treatment decisions. Pharmacotherapy for benign prostatic hyperplasia (BPH)/LUTS can cause side‐ effects affecting sexual function. Hence, 5α‐reductase inhibitors such as finasteride and dutasteride are associated with a greater risk of ED, ejaculatory disorders (EjD) and decreased libido than is placebo. Among α 1 ‐adrenergic blockers, tamsulosin is associated with an increased risk of EjD. However, some α 1 ‐adrenergic blockers can also have a positive impact on erection. This is the case for alfuzosin, which has been shown to enhance erectile function in experimental models, probably by reducing the sympathetic tone and thus relaxing corpus cavernosum smooth muscle cells. Phosphodiesterase 5 (PDE‐5) inhibitors are commonly used to treat ED. There is increasing evidence that they might also have a beneficial effect on LUTS, probably through the nitric‐oxide pathway. Nitric oxide is an important mediator of the relaxation of isolated bladder and urethral smooth muscle, and could modulate prostatic smooth muscle tone. α 1 ‐adrenergic blockers and PDE‐5 inhibitors can therefore have a positive impact on both ED and LUTS. Although placebo‐controlled studies are needed to confirm the impact of these drugs, alone or combined, on both ED and LUTS, this reinforces the need for a common approach to managing these two highly prevalent and bothersome conditions.